About EAM 2201
Whilst CB1 receptor activation lowered neurotransmitter release in any way important courses of Purkinje mobile synapses, this was not achieved by one molecular system.Our in vitro benefits advise that EAM-2201 need to be examined regarding probable in vivo pharmacokinetic drug–drug interactions because of time-dependent inhibition of CYP2C8, CYP